Abivax ADR [ABVX] stock prices are down -3.08% to $119.12 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ABVX shares have gain 7.91% over the last week, with a monthly amount glided 31.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abivax ADR [NASDAQ: ABVX] stock has seen the most recent analyst activity on November 06, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $176. Previously, Barclays started tracking the stock with Overweight rating on October 13, 2025, and set its price target to $142. On July 23, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $71 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $12 on March 20, 2025. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $33 as its price target on December 04, 2024. Laidlaw started tracking with a Buy rating for this stock on July 29, 2024, and assigned it a price target of $48. In a note dated May 20, 2024, BTIG Research initiated a Buy rating and provided a target price of $43 on this stock.
The stock price of Abivax ADR [ABVX] has been fluctuating between $4.77 and $126.99 over the past year. Currently, Wall Street analysts expect the stock to reach $129.33 within the next 12 months. Abivax ADR [NASDAQ: ABVX] shares were valued at $119.12 at the most recent close of the market. An investor can expect a potential return of 8.57% based on the average ABVX price forecast.
Analyzing the ABVX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -33.06%, Pretax Profit Margin comes in at -33.1%, and Net Profit Margin reading is -32.44%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is 50.78 and Total Capital is -27.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 114.54 points at the first support level, and at 109.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 123.23, and for the 2nd resistance point, it is at 127.33.
Ratios To Look Out For
It’s worth pointing out that Abivax ADR [NASDAQ:ABVX]’s Current Ratio is 0.77. On the other hand, the Quick Ratio is 0.77, and the Cash Ratio is 0.54.
Transactions by insiders
Recent insider trading involved Sofinnova Crossover I SLP, Affiliate, that happened on Oct 28 ’25 when 1.2 million shares were purchased.
